Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action [0.03%]
针对具有多种作用机制的CD20阳性癌症的Rituximab/CD3 T细胞接合器的计算设计及其生物活性验证
Wenyan Cai,Jianbo Dong,Sachith Gallolu Kankanamalage et al.
Wenyan Cai et al.
Background: Bispecific T cell engaging antibodies (TEAs) with one arm targeting a cancer antigen and another arm binding to CD3 have demonstrated impressive efficacy in multiple clinical studies. However, establishing a s...
Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers [0.03%]
针对ROR1的抗体药物偶联物在血液系统恶性肿瘤和实体瘤中的研究进展观点
Haiyong Peng
Haiyong Peng
Antibody-drug conjugates (ADCs) are targeted therapeutics generated by conjugation of cytotoxic small molecules to monoclonal antibodies (mAbs) via chemical linkers. Due to their selective delivery of toxic payloads to antigen-positive canc...
Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody [0.03%]
用于检测抗CD38×CD3双特异性抗体生物活性的报告基因方法的开发
Hui Xiong,Fengyan Luo,Pengfei Zhou et al.
Hui Xiong et al.
Background: A T cell-redirecting bispecific antibody (bsAb) consisting of a tumor-binding unit and a T cell-binding unit is a large group of antibody-based biologics against death-causing cancer diseases. The anti-CD38 ×...
Targeting the cancer neoantigens p53 and KRAS with TCR mimic antibodies [0.03%]
靶向癌症新抗原p53和KRAS的TCR模拟抗体
Zhijian Duan,Mitchell Ho
Zhijian Duan
Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice [0.03%]
以乙型肝炎表面抗原为靶点的治疗性疫苗诱导新型猴单克隆抗体有效抑制小鼠中的乙型肝炎病毒
Yuanzhi Chen,Xinchu Xiang,Ruoyao Qi et al.
Yuanzhi Chen et al.
Background: We have previously obtained a mouse anti-hepatitis B surface antigen (HBsAg) antibody E6F6 with long-lasting serum HBsAg clearance effects. The E6F6 epitope-based protein CR-T3-SEQ13 (HBsAg aa 113-135) vaccina...
Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential [0.03%]
针对SARS-CoV-2刺突蛋白加速抗体发现以期COVID-19治疗潜力
Tracey E Mullen,Rashed Abdullah,Jacqueline Boucher et al.
Tracey E Mullen et al.
Background: Rapid deployment of technologies capable of high-throughput and high-resolution screening is imperative for timely response to viral outbreaks. Risk mitigation in the form of leveraging multiple advanced techn...
Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors [0.03%]
MRG002的临床前评估：一种针对HER2具有较强抗肿瘤活性的新型抗体药物复合物
Hu Li,Xiao Zhang,Zhenyi Xu et al.
Hu Li et al.
Background: ERBB2 is a proto-oncogene of multiple cancers including breast and gastric cancers with HER2 protein overexpression or gene amplification and has been proven clinically as a valid target for these cancers. HER...
Antony Yerabham,Mitchell Ho
Antony Yerabham
Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC [0.03%]
以增强ADCC效力为目标的去岩藻糖基化IgG对FcγRIIIA/FcγRIV的跨物种高敏感性
Changchuin Mao,Richard Near,Xuemei Zhong et al.
Changchuin Mao et al.
Background: Expressing afucosylated human IgG1 antibodies with Chinese hamster ovary (CHO) cells deficient of α-(1,6)-fucosyltransferase (FUT8) is being more and more accepted as a routine method to enhance antibody-depe...
Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers [0.03%]
应用集成计算抗体工程平台设计SARS-CoV-2中和抗体
Saleh Riahi,Jae Hyeon Lee,Shuai Wei et al.
Saleh Riahi et al.
As the COVID-19 pandemic continues to spread, hundreds of new initiatives including studies on existing medicines are running to fight the disease. To deliver a potentially immediate and lasting treatment to current and emerging SARS-CoV-2 ...